Research programme: immunology, inflammation and cardiometabolic disease therapeutics - BioMotiv/Takeda
Latest Information Update: 03 Oct 2014
At a glance
- Originator BioMotiv
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Cardiovascular disorders; Immunological disorders; Inflammation
Most Recent Events
- 25 Sep 2014 Early research in Inflammation in USA (unspecified route)
- 25 Sep 2014 Early research in Immunological disorders in USA (unspecified route)
- 25 Sep 2014 Early research in Cardiovascular disorders in USA (unspecified route)